Business Context and Reporting Period
This Form 8-K was filed by Ocuphire Pharma, Inc. (trading symbol: OCUP) on January 31, 2022. The report addresses "Other Events" (Item 8.01) concerning the issuance of a press release regarding new data and updates on the Company's APX3330 and Nyxol clinical programs. The filing incorporates the press release as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical program updates and does not contain financial statements or quantitative financial data.
Material Changes
The material change reported is the announcement of new data and updates regarding the APX3330 and Nyxol clinical programs. No financial comparisons to prior periods are included in this document.
Guidance, Outlook, and Risks
Management commentary is limited to the reference of the press release filed as Exhibit 99.1. The filing explicitly states that information on any website referenced in the press release is not incorporated by reference. No specific forward-looking guidance, risk factors, or contingencies are detailed within the body of this 8-K form.
Investor Verification Checklist
- Review Exhibit 99.1 (the Press Release dated January 31, 2022) for specific details on the APX3330 and Nyxol clinical data.
- Verify the current status of the APX3330 and Nyxol clinical trials through independent regulatory databases or subsequent filings.
- Confirm that no financial metrics were omitted from this specific 8-K, as it is a non-financial event report.